CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
05 mai 2022 18h12 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the...
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
05 mai 2022 16h05 HE
|
Celyad Oncology SA
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM)Dialogue continues with...
Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program
04 mai 2022 07h00 HE
|
Starton Therapeutics, Inc.
Independent safety review approved dose escalation and initiation of next dosing cohortSTAR-LLD generally well tolerated in all subjects dosed to dateOn track to complete dosing of all cohorts in May...
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application Protecting Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents
04 oct. 2021 07h00 HE
|
Starton Therapeutics, Inc.
PARAMUS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, today...
Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression and Excellent Tolerability
30 sept. 2021 07h10 HE
|
Starton Therapeutics, Inc.
PARAMUS, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies,...
Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth With A Gamut of Pharma Companies Involved Worldwide
18 mai 2021 20h20 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, May 18, 2021 (GLOBE NEWSWIRE) -- Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth with a Gamut of Pharma Companies Involved Worldwide The Multiple Myeloma...
Comprehensive Analysis of 250+ Key Companies Developing 250+ Novel CAR-T Therapies: DelveInsight
20 avr. 2021 20h50 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, April 20, 2021 (GLOBE NEWSWIRE) -- Comprehensive Analysis of 250+ Key Companies Developing 250+ Novel CAR-T Therapies: DelveInsight More than 50% of trials investigating...
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma
07 déc. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported...
Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B (Anti-BCMAxCD3) at the 62nd Annual Meeting of the American Society of Hematology
19 nov. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today...
Telo Genomics Announces Study Results Showing That TeloView® Differentiates Between Stable Smoldering Multiple Myeloma Patients and Patients That Progressed to Active Multiple Myeloma
16 nov. 2020 11h13 HE
|
Telo Genomics Corp.
TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce the positive results of its smoldering multiple myeloma proof of concept...